Impact of glucagon-like peptide 1 receptor agonist liraglutide and dipeptidyl peptidase-4 inhibitor sitagliptin on bowel cleaning and gastrointestinal symptoms in type 2 diabetes

被引:10
|
作者
Tong, Yan [1 ]
Huang, Jian Qing [1 ]
Chen, Yang [1 ]
Tu, Mei [1 ]
Wang, Wei [1 ]
机构
[1] Fujian Med Univ, Longyan Affiliated Hosp 1, Longyan, Fujian, Peoples R China
关键词
liraglutide; sitagliptin; bowel preparation quality; gastrointestinal discomfort; gastrointestinal motility; DOSE POLYETHYLENE-GLYCOL; GLUCOSE; COLONOSCOPY; EXENATIDE; SUPERIOR; MOTILITY; TRANSIT;
D O I
10.3389/fphar.2023.1176206
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Objective: Glucagon-like peptide 1 receptor agonists (GLP-1 RAs) and dipeptidyl peptidase-4 inhibitors (DPP-4i) profoundly affect the gastrointestinal motor system, which may increase the incidence of inadequate bowel cleaning and gastrointestinal symptoms. Hence, this observational study mainly aimed to assess the influence of GLP-1 RAs liraglutide and DPP-4i sitagliptin on bowel preparation in type 2 diabetes (T2DM). Method: This observational study consecutively enrolled T2DM scheduled for a colonoscopy. Participants were prospectively separated into the liraglutide group (n = 120), sitagliptin group (n = 120), and control group (n = 120) based on the current hypoglycemic regimen. 3L split-dose polyethylene glycol regimens were used for bowel preparation. Experienced gastrointestinal endoscopists conducted colonoscopies. Lawrance Bowel-Preparation Tolerability Questionnaire and Boston Bowel Preparation Scale (BBPS) were conducted to assess bowel cleaning quality, tolerability, and safety. Results: The incidence of inadequate bowel cleaning was 17.5% in the liraglutide group, 20.5% in the sitagliptin group, and 21.7% in the control group. The difference among the three groups was not statistically significant (p = 0.927). Meanwhile, there were no significant differences in the mean BBPS, cecal intubation time, and polyp-detecting rates among the three groups (all p > 0.0.05). Nausea, vomiting, and bloating scores were increased in the liraglutide group compared with the other two groups (p < 0.05), whereas most were mild or very mild. Subgroup analyses showed that the incidence of inadequate bowel cleaning in T2DM with diabetic peripheral neuropathy (DPN) was increased in the liraglutide group compared with the sitagliptin group (61.3% vs. 32.1%, p = 0.022) and control group (61.3% vs. 32.8%, p = 0.025). Conclusion: GLP-1RA liraglutide or DPP-4i sitagliptin did not significantly increase the incidence of inadequate bowel cleaning and gastrointestinal symptoms during bowel preparation. Liraglutide may increase the incidence of inadequate bowel preparation in patients with DPN. This study reveal that more attention and aggressive bowel preparation regimens should be given to the T2DM with DPN.
引用
收藏
页数:9
相关论文
共 50 条
  • [1] The effect of dipeptidyl peptidase-4 inhibitor and glucagon-like peptide-1 receptor agonist in gestational diabetes mellitus: a systematic review
    Chen, Chengcong
    Huang, Ying
    Dong, Guoqing
    Zeng, Yongmei
    Zhou, Ziqiong
    GYNECOLOGICAL ENDOCRINOLOGY, 2020, 36 (05) : 375 - 380
  • [2] Incretin-based treatment of type 2 diabetes: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors
    Deacon, Carolyn F.
    DIABETES OBESITY & METABOLISM, 2007, 9 : 23 - 31
  • [3] Glucagon-like peptide receptor agonists and dipeptidyl peptidase-4 inhibitors in the treatment of diabetes: a review of clinical trials
    Madsbad, Sten
    Krarup, Thure
    Deacon, Carolyn F.
    Holst, Jens J.
    CURRENT OPINION IN CLINICAL NUTRITION AND METABOLIC CARE, 2008, 11 (04) : 491 - 499
  • [4] Utilization of Glucagon-Like Peptide-1 Receptor Agonist and Dipeptidyl Peptidase-4 Inhibitors at the Veterans Health Administration
    Krishnan, Aditya
    Suryanarayanan, Sowmya K.
    Mansi, Ishak A.
    JOURNAL OF PHARMACY TECHNOLOGY, 2024, 40 (05) : 223 - 229
  • [5] Association of Glucagon-Like Peptide-1 Receptor Agonist vs Dipeptidyl Peptidase-4 Inhibitor Use With Mortality Among Patients With Type 2 Diabetes and Advanced Chronic Kidney Disease
    Jia-Jin Chen
    Chao-Yi Wu
    Chang-Chyi Jenq
    Tao-Han Lee
    Chung-Ying Tsai
    Hui-Tzu Tu
    Yu-Tung Huang
    Chieh-Li Yen
    Tzung-Hai Yen
    Yung-Chang Chen
    Ya-Chung Tian
    Chih-Wei Yang
    Huang-Yu Yang
    JAMA NETWORK OPEN, 2022, 5 (03)
  • [6] Is glucagon-like peptide-1 fully protected by the dipeptidyl peptidase 4 inhibitor sitagliptin when administered to patients with type 2 diabetes?
    Andersen, Emilie S.
    Lund, Asger
    Bagger, Jonatan I.
    Andreasen, Camilla
    Grondahl, Magnus F.
    Deacon, Carolyn F.
    Hartmann, Bolette
    Holst, Jens J.
    Knop, Filip K.
    Vilsboll, Tina
    DIABETES OBESITY & METABOLISM, 2018, 20 (08) : 1937 - 1943
  • [7] Acute hemodynamic and renal effects of glucagon-like peptide 1 analog and dipeptidyl peptidase-4 inhibitor in rats
    Zhou, Xiaoyan
    Huang, Chin-hu
    Lao, Julie
    Pocai, Alessandro
    Forrest, Gail
    Price, Olga
    Roy, Sophie
    Kelley, David E.
    Sullivan, Kathleen A.
    Forrest, Michael J.
    CARDIOVASCULAR DIABETOLOGY, 2015, 14
  • [8] The addition of metformin and glucagon-like peptide-1 receptor agonist or dipeptidyl-peptidase-4 inhibitor to insulin for latent autoimmune diabetes in adults
    Sumie Moriyama
    Hidekatsu Yanai
    International Journal of Diabetes in Developing Countries, 2014, 34 : 56 - 56
  • [9] The addition of metformin and glucagon-like peptide-1 receptor agonist or dipeptidyl-peptidase-4 inhibitor to insulin for latent autoimmune diabetes in adults
    Moriyama, Sumie
    Yanai, Hidekatsu
    INTERNATIONAL JOURNAL OF DIABETES IN DEVELOPING COUNTRIES, 2014, 34 (01) : 56 - 56
  • [10] Cardiovascular Effects of Dipeptidyl Peptidase-4 Inhibitors and Glucagon-Like Peptide-1 Receptor Agonists: a Review for the General Cardiologist
    Patel, Kershaw, V
    Sarraju, Ashish
    Neeland, Ian J.
    McGuire, Darren K.
    CURRENT CARDIOLOGY REPORTS, 2020, 22 (10)